STOCK TITAN

ROSEN, GLOBAL INVESTOR COUNSEL, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Negative)
Tags

NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.

On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma's "unaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon." Sonoma continued that the financial statements for this time period "contained material errors" and that "the Company will need to restate them."

On this news, Sonoma's share price fell $1.10 per share, or more than 14%, over the next few trading days to close at $6.63 per share on November 20, 2020.

Rosen Law Firm is preparing a securities lawsuit on behalf of Sonoma shareholders. If you purchased securities of Sonoma please visit the firm's website at http://www.rosenlegal.com/cases-register-1992.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at mailto:pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.  Rosen Law Firm's attorneys are ranked and recognized by numerous independent and respected sources.  Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com 
pkim@rosenlegal.com 
cases@rosenlegal.com 
www.rosenlegal.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-global-investor-counsel-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc--snoa-301210408.html

SOURCE Rosen Law Firm, P.A.

Sonoma Pharmaceuticals, Inc.

NASDAQ:SNOA

SNOA Rankings

SNOA Latest News

SNOA Stock Data

3.68M
15.35M
1.56%
1.95%
0.19%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
BOULDER

About SNOA

sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal